Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Own Cameco Corporation (USA) (CCJ)?

Page 1 of 2

Strong industry fundamentals make nuclear power a wise investment. Economically, it is more viable than any method of electricity generation besides hydroelectric which itself is severely limited geographically in where it can be produced. Environmentally, the generation of nuclear power does not result in the release of any toxic air pollutants or greenhouse gasses. Global consumption of uranium has exceeded production in every year since 1985, with the gap being bridged by secondary sources. One of the largest of those secondary sources is the Russian highly enriched uranium (HEU) agreement whose expiration this year will  considerably reduce supply (24 million pounds per year, about 15% of 2011 consumption). Unfortunately the Fukushima disaster has resulted in a negative short term outlook for the industry. But the best in the industry will weather the storm and patient investors will be able to reap rewards from a form of energy that will certainly be there 20 years from now.

Cameco Corporation (USA) (NYSE:CCJ)Enter Cameco Corporation (USA) (NYSE:CCJ)

The CAnadian Mining and Energy Corporation, or Cameco Corporation (USA) (NYSE:CCJ), is the world’s second largest producer of uranium behind only Kazatomprom, which is owned by the government of Kazakhstan. Despite adverse market conditions Cameco’s uranium segment has remained profitable, generating gross profits of 504 and 632 million dollars in 2012 and 2011, respectively. The same cannot be said for Rio Tinto plc (ADR) (NYSE:RIO). In 2011 Rio Tinto lost just over 100 million dollars producing 7 million pounds of uranium. A 38% increase in production didn’t stop the bleeding as losses climbed to 178 million. This year Rio Tinto is decreasing production slightly from 2012 levels and praying they don’t lose too much money. Which makes sense for a company who has several other segments actually making a profit. This presents an opportunity for Cameco, a pure play nuclear investment, to take some market share from a competitor who has clearly shown that the uranium business is not their top priority.

An 8.5 Billion Dollar Price Tag

Most of us probably don’t have 8.5 billion dollars lying around to purchase Cameco, but as investors considering buying even a single share we would be wise to think as if we were purchasing the entire company. So is Cameco worth 8.5 billion dollars? If you had bought Cameco 10 years ago by now the Canadians would have put 2.5 billion dollars of retained earnings in your pocket. On top of that you would have received nearly 860 million dollars in dividends, with no year yielding less in distributions than the last. Cameco has generated 3.36 billion dollars in cash for its owners over the past 10 years. The facts lead me to believe the next 10 years will yield even greater results for the owners of Cameco. The total amount of cash used to pay dividends has climbed 566% for Cameco over the past 10 years, since 2009 distributions have been increased by 67%. Retained earnings will rise with the price of uranium, widely considered to be near a bottom, and increased production. Cameco intends produce 36 million pounds of uranium in 2018, they produced 21.9 million pounds last year. What would you say is a fair price for a company that produced 3.36 billion dollars for its owners over the past 10 years and is planning to nearly double its production? 8.5 billion dollars certainly seems fair to me.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!